Technical Analysis for VRCA - Verrica Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 12.71 6.18% 0.74
VRCA closed up 6.18 percent on Friday, February 15, 2019, on 84 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Down
See historical VRCA trend table...

Date Alert Name Type % Chg
Feb 15 20 DMA Support Bullish 0.00%
Feb 15 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Feb 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Feb 15 Spinning Top Other 0.00%
Feb 15 Outside Day Range Expansion 0.00%
Feb 15 Wide Bands Range Expansion 0.00%
Feb 14 MACD Bearish Signal Line Cross Bearish 6.18%
Feb 14 20 DMA Support Bullish 6.18%
Feb 14 1,2,3 Pullback Bullish Bullish Swing Setup 6.18%
Feb 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 6.18%

Older signals for VRCA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: 2019-02-13
Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
Health Pharmaceutical Pharmaceutical Industry Medication Pharmaceutical Products Clinical Trial Common Warts Skin Diseases Treatment Of Skin Diseases
Is VRCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 12 Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
Jan 24 Verrica Pharmaceuticals: Molluscum Contagiosum, Really?
Jan 7 Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
Jan 3 West Chester pharma firm to seek FDA OK for skin treatment
Jan 3 Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
Dec 26 Microcaps mostly among midday movers
Dec 21 The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
Dec 20 Are Insiders Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock?
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
Dec 19 The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas
See more VRCA news...
Indicators
Indicator Value
52 Week High 23.29
52 Week Low 6.44
Average Volume 50,812
200-Day Moving Average 0.0
50-Day Moving Average 10.6004
20-Day Moving Average 12.066
10-Day Moving Average 13.028
Average True Range 1.2304
ADX 32.07
+DI 21.0672
-DI 12.4275
Chandelier Exit (Long, 3 ATRs ) 10.7038
Chandelier Exit (Short, 3 ATRs ) 13.391199999999999
Upper Bollinger Band 14.4454
Lower Bollinger Band 9.6866
Percent B (%b) 0.64
BandWidth 39.439748
MACD Line 0.5995
MACD Signal Line 0.6689
MACD Histogram -0.0693
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.27
Resistance 3 (R3) 16.17 14.90 15.67
Resistance 2 (R2) 14.90 13.99 14.94 15.47
Resistance 1 (R1) 13.80 13.43 14.35 13.90 15.28
Pivot Point 12.53 12.53 12.80 12.57 12.53
Support 1 (S1) 11.43 11.62 11.98 11.53 10.14
Support 2 (S2) 10.16 11.06 10.20 9.95
Support 3 (S3) 9.06 10.16 9.75
Support 4 (S4) 9.16